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Capsule Summary 34 
Immunoproteomics, IgE-inhibition assays and cDNA-cloning reveals that ash and olive 35 
allergenic protein profiles are mostly equivalent, thus explaining their high cross-36 
reactivity. Our data suggest simplifying diagnosis of patients by using indistinctly ash or 37 
olive pollen. 38 
 39 
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To the Editor: 44 
Ash (Fraxinus excelsior) is widely distributed in Northern and Central Europe. 45 
Although yearly ash pollen counts are in the range of 1000 grains/m3, its clinical 46 
relevance has been undervalued because ash pollination overlaps with that of 47 
Betulaceae.1 Subsequently, ash has not been included in diagnostic assays,2 although 48 
is responsible for extensive pollinosis in Alsace (France) and Austria where ash 49 
pollination occurs immediately after birch,2 and Switzerland where it is as frequent as 50 
birch pollinosis.3 51 
Allergic patients are commonly diagnosed and treated with protein extracts from 52 
natural sources. An alternative approach for allergy diagnosis and personalized 53 
treatment of patients consists of the utilization of purified allergens. Thus, it is 54 
necessary to know the near complete allergogram of the source responsible for the 55 
sensitization. 56 
Fra e 1 is the only ash pollen allergen isolated, produced as recombinant 57 
protein and characterized,4 despite the complexity of the IgE-reactive protein profile 58 
observed by 1D-electrophoresis (1DE) analysis of F. excelsior pollen.4, 5 We therefore 59 
performed an extensive 2D-electrophoresis (2DE) analysis to identify the IgE-reactive 60 
proteins content using serum of 25 ash pollen sensitized patients with IgE reactivity to 61 
ash and olive pollen extracts by ELISA (see Table E1 in this article’s Online Repository 62 
at www.jacionline.org). On average, silver-staining gels showed 165 ± 15 spots 63 
between isoelectric points (pI) 3.5 to 8.2 and molecular masses (MW) between 4 and 64 
70 kDa (see Figure 1A). To visualize IgE-binding proteins, 2D-immunoblots were 65 
performed using two independent pools containing 8 different ash pollen-allergic 66 
patient’s sera (see Figure 1B and 1C). We found 35 ± 2 IgE-binding proteins with pIs 67 
from 3.8 to 8.1 and MW ranging between 8 and 66 kDa. A main group of IgE spots 68 
centered at mildly acidic-neutral pI and about 18-22 kDa corresponded to Fra e 1 69 
isoforms.4, 5 70 




We hypothesized that most of the IgE-reactive observed bands might 71 
correspond to proteins with similar molecular features (pI and MW) to previously 72 
described olive pollen allergens: Ole e 1, Ole e 2, Ole e 3, Ole e 6, Ole e 7, Ole e 9, 73 
Ole e 10, Ole e 11 and Ole e 12.6 To address this question, we then performed a 74 
complete immunoproteomic study of ash pollen extract by 2DE using polyclonal 75 
antisera raised against the most relevant olive pollen allergens (see Figure 1D). We 76 
identified IgG-reactive proteins and named them as Fra e 1, Fra e 2, Fra e 3, Fra e 6, 77 
Fra e 7, Fra e 9, Fra e 11, and Fra e 12, according to the olive homologues recognized 78 
by the rabbit antisera. All of them and their isoforms were responsible for most of the 79 
identified IgE-reactive proteins (see Figure 1B and 1C). Fra e 10 was only detected by 80 
1DE (data not shown). 81 
These findings suggest high sequence identity between olive and ash pollen 82 
allergens. To confirm this hypothesis, cDNA encoding six ash pollen allergens not 83 
previously reported (Fra e 2, Fra e 3, Fra e 6, Fra e 10, Fra e 11, and Fra e 12) was 84 
amplified by PCR, cloned and sequenced (see Table E2 in this article's Online 85 
Repository at www.jacionline.org).4 cDNA encoding the complete sequences of 6 of the 86 
most IgE-reactive allergens from ash pollen rendered polypeptides ranging from 50 87 
amino acids for Fra e 6 to 341 for Fra e 11 (see Figure 1E). Ash allergens possessed 88 
similar physicochemical properties to those from olive pollen: acidic to mildly acidic 89 
proteins (4.3 to 6.5) except Fra e 7 with a basic pI of 8.2; low to medium MW (5.8 to 90 
37.4 kDa) and the presence of signal peptides for Fra e 6, Fra e 10 and Fra e 11. The 91 
sequence identity between ash and olive pollen allergens ranged between 84 and 97%, 92 
and similarity from 94 to 99%, except for Fra e 11 that presented the lowest identity 93 
and similarity (79 and 90%, respectively) with its olive counterpart (see Figure 1E).  94 
Consistently with the high amino acid sequence identity and similarity between 95 
ash and olive pollen allergens, we hypothesized that purified olive pollen allergens 96 
could be used to assess the significance, potency and prevalence of ash pollen 97 
allergens. We then performed IgE-inhibition assays of the ash pollen extract with ash 98 




sensitized patients sera and the panel of purified olive pollen allergens as inhibitors. By 99 
densitometry of 1DE and 2DE IgE-inhibition assays, we measured a 95% reduction of 100 
the IgE-binding obtained with the IgE serum pool without inhibitors (see Figure 2A and 101 
2B). The residual IgE-positive signal might be due to the recognition of specific 102 
isoforms not so cross-reactive to olive pollen allergens because of differences in their 103 
amino acid sequence or glycosylation patterns. Alternatively, the presence of other 104 
allergens different from those present in olive pollen should not be discarded. In a 105 
recent publication analyzing ash pollen components by proteomics based on 2D and 106 
mass spectrometry,7 the authors identified Fra e 1, Fra e 2, and Fra e 3 as relevant 107 
allergens, and E-galactosidase, malate deshydrogenase, and a 4-EF hand Ca-binding 108 
protein as minor ash pollen allergens; with the vast majority of major allergen spots 109 
unidentified.7 Then, the residual 5% of the IgE-reactivity observed in the IgE inhibition 110 
assays might be associated to these minor allergens.7 111 
As IgE-inhibition assays validated the use of purified olive pollen allergens to 112 
characterize the IgE immune response of ash pollen sensitized patients, we tested their 113 
IgE-binding ability by ELISA. The deduced prevalence for the cross-reactive ash 114 
allergens ranged between 64 to 92% for the major allergens Fra e 1, Fra e 2, Fra e 9 115 
and Fra e 11 and between 4 to 32% for the minor allergens Fra e 3, Fra e 6, Fra e 7, 116 
Fra e 10 and Fra e 12 (see Figure 2C and 2D). These findings are in accordance with 117 
previous reports involving related and non-related allergenic sources, except for Fra e 118 
10 that was previously described as major allergen in olive pollen.6, 8 119 
Collectively, our findings show that the F. excelsior allergogram responsible for 120 
the allergy symptoms in ash-sensitized patients is highly similar to that obtained from 121 
O. europaea, which supports the high cross-reactivity of patients to both pollens. 122 
Moreover, the high sequence identity of olive and ash pollen allergens and the IgE-123 
inhibition results suggest using indistinctly purified allergens from ash or olive pollen for 124 
diagnosis. For treatment, the most prevalent pollen extract in the living area of the 125 
sensitized patient should be used. For personalized treatment, a comparative trial with 126 




patients receiving either olive or ash allergens should be made to ensure that their 127 
differences do not affect patient’s desensitization. 128 
 129 
Additional information is available (see this article’s Methods section and References in 130 
the Online Repository at www.jacionline.org). 131 
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Figure legends 180 
 181 
Figure  1. IgE-reactive proteins identified by immunoproteomic profiling of ash-182 
pollen extract. (A) 2DE separation of ash-pollen extract followed by silver staining. IgE-183 
immunoblot after 2DE using (B) 15% or (C) 17% polyacrilamide gels. IgE-184 
immunostaining was performed with a selected equivolumetric pool of 8 sera directed 185 
against high MW allergens (B) or 8 sera directed to low MW allergens (C).4, 5 (D) 2DE 186 
as in B and C, and immunostaining with the indicated polyclonal antisera raised against 187 
known olive pollen allergens to identify the main IgE-reactive components of ash pollen 188 
extract. The IgE-reactive spots named in panels B and C were identified according to 189 
the IgG reactivity in panel D. (E) Amino acid sequences of the six new allergens from 190 
F. excelsior pollen and alignment with their O. europaea counterparts. Dots, same 191 
amino acid than reference. Dash, gaps. Identity and similarity were calculated without 192 
the theoretical signal peptide. Accession numbers: Fra e 2 (KC920922), Fra e 3 193 
(KC920923), Fra e 6 (KC920921), Fra e 10 (KC920924), Fra e 11 (KC920915), Fra e 194 
12 (EF626802), Ole e 2 (A4GE44), Ole e 3 (O81092), Ole e 6 (O24172), Ole e 10 195 
(Q84V39), Ole e 11 (D8VPP5), and Ole e 12 (E1U332). 196 
 197 
Figure 2. IgE-binding inhibition assays to ash pollen extract and allergenic 198 
contribution of ash-pollen allergens. (A) Inhibition of the IgE binding to ash pollen 199 
extract subjected to 1DE using a pool of 8 randomly selected sera different from those 200 
used in Figure 1 to avoid any bias towards any particular allergen and a cocktail of 2.5 201 
μg/mL of each of the olive pollen allergens homologous to Fra e 1, Fra e 2, Fra e 3, Fra 202 
e 6, Fra e 7, Fra e 9, Fra 10, Fra e 11 and Fra e 12 as inhibitors. -, no inhibitor. +, with 203 
inhibitors. N, non-atopic serum. (B) Inhibition of the IgE binding to ash pollen extract 204 
subjected to 2DE using the same olive allergen cocktail. Left, no inhibitor. Right, with 205 
inhibitors. A non-atopic serum was used as control. (C-D) Specific IgE levels for each 206 
olive pollen allergen in OD for the 25 ash pollen sensitized sera obtained by ELISA. 207 
Median value (red dot) and standard deviation (red error bars) are also represented. 208 
Supplementary Methods 
Pollen protein extracts 
Pollens from Fraxinus excelsior and Olea europaea were obtained from ALK-Abelló 
(Madrid, Spain). Pollen protein extracts were obtained by saline extraction as described 
previously.E1, E2 Protein extract concentration was determined by Lowry method 
according to established protocols.  
 
Serum samples, allergenic proteins and antibodies 
The Ethical Committee of the Complutense University (Madrid, Spain) approved 
the protocols used for experimental work with mice and all the methodology related to 
the use of human sera in the study.  
Twenty-five patients from Strasbourg (France) with pollinosis to ash (see Table 
E1 in this article’s Online Repository at www.jacionline.org), a class radioallergosorbent 
test result ranging from 1 to 6 as determined using the CAP-RAST method (Amersham 
Pharmacia Biotech, Uppsala, Sweden), positive skin prick test reactions to ash pollen 
extract, and no migratory background to or from the Mediterranean area were included 
in this study.E1, E2 Furthermore, one non-atopic patient was used as a negative control. 
All patients provided informed consent. Patient’s sera were positive to ash and olive 
pollen extract by ELISA (correlation of 0.93). 
Polyclonal antiserum against indicated natural purified olive pollen allergens 
were prepared by immunizing separately New Zealand white rabbits in a 6-week period 
by weekly injections of the protein (100 Pg) in complete Freund adjuvant. Horseradish 
peroxidase-labeled goat polyclonal antibody against rabbit IgG was obtained from Bio-
Rad (Richmond, Calif). Mouse monoclonal antibody against human IgE was kindly 
donated by ALK-Abelló (Madrid, Spain). Horseradish peroxidase-labeled rabbit 
polyclonal antibody against mouse IgG was purchased from Dako (San Just Desvern, 
Barcelona, Spain). 
Repository - Unmarked Supplementary Material and Methods Text
Allergenic olive proteins were purified according to previously published 
protocols,E3 and concentration determined by micro BCA Protein Assay kit (Pierce). 
 
1D-, 2D-electrophoresis and analytical procedures 
  SDS-PAGE was alternatively performed in 15% or 17% polyacrylamide gels 
under reducing conditions in the presence of 5% E-mercaptoethanol according to 
established protocols. Proteins were stained with Coomassie Blue R-250 (Sigma-
Aldrich, Química, Spain). Molecular mass was determined with protein markers MW-
SDS-70L (Sigma-Aldrich). 
2DE was performed in a PROTEAN IEF Cell using 7 cm length, pH 3-10 linear 
ReadyStrip IPG (Bio-Rad) under reducing conditions in the presence of 
tributylphosphine, and/or dithiothreitol, and iodoacetamide, followed by 15% or 17% 
SDS-PAGE. Proteins were visualized after silver staining or alternatively transferred to 
nitrocellulose membranes for immunostaining with ash pollen sensitized patient’s sera 
or polyclonal antisera. Experiments were performed in triplicate. Images show a 
representative image of the experiment. 
   
Immunological assays 
  Proteins were alternatively transferred to nitrocellulose membranes (Amersham 
Biosciences) after SDS-PAGE or 2DE under reducing conditions. Membranes were 
incubated with individual or an equivolumetric pool of human sera (diluted 1:10), mouse 
anti-human IgE monoclonal antibody (Alk-Abelló) (diluted 1:5000) and rabbit anti-
mouse IgG horseradish peroxidase-labeled antibody (Dako) (diluted 1:2500). 
Alternatively, membranes were incubated with rabbit polyclonal antisera raised against 
olive pollen allergens (diluted 1:10000) followed by goat anti-rabbit IgG horseradish 
peroxidase-labeled polyclonal antibody (Bio-Rad) (diluted 1:3000) as described.E1, E4 
For immunoblotting inhibition assays an equivolumetric pool of 8 sera (diluted 1:10) 
was preincubated with PBS, or 2.5 Pg/mL of each purified allergen as inhibitors.E1, E4 
Chemiluminiscent signal was developed by ECL-Western blotting reagent (Amersham 
Bioscience). Immunoblotting inhibition assays were quantified by densitometry using 
the Multi Gauge software (Fujifilm, Barcelona, Spain). Percentage of IgE inhibition was 
calculated considering the IgE binding signal with the membranes incubated with the 
IgE serum pool in absence of inhibitors as 100%.  
Indirect ELISA was performed in 96 well plates coated with 0.1 Pg of purified 
proteins or 20 Pg of pollen extract per well. Assays were performed using individual 
human serum samples, or alternatively, an equivolumetric pool of human sera (n=5) 
(diluted 1:10), previously adsorbed with indicated concentrations of inhibitors for the 
inhibition assays.E1, E4 Binding of human IgE or specific polyclonal antisera was 
detected as above described. Signal was developed with o-phenylenediamine diluted 
in citrate buffer, stopped with 1 M H2SO4, and measured at 492 nm in an iMark 
Microplate Absorbance Reader (Bio-Rad). ELISA experiments were performed in 
triplicate and absorbance values above 0.1 were taken as positives. 
  
Cloning strategy  
  cDNA from F. excelsior pollen was synthesized from total RNA using the 
SMART RACE cDNA amplification kit (BD Biosciences-Clontech, Madrid, Spain) 
according to the manufacturer instructions and directly used as template in PCR 
reactions. Amplification of F. excelsior pollen allergens by PCR was performed using 
degenerate and non-degenerate oligonucleotides (see Table E2 in this article’s Online 
Repository at www.jacionline.org) designed from conserved nucleotide sequences from 
related (olive) and non-related phylogenetically homologues as previously described.E5, 
E6 PCR products were cloned into the pCR2.1 plasmid (Invitrogen, Groningen, The 
Netherlands), and DNA from 4-6 clones of each construction sequenced using M13 
forward and M13 reverse oligonucleotides.  
 
Statistical analysis, amino acid sequences analysis, alignment, and modeling  
  We used Microsoft Excel 2007 for the analysis of ELISA data sets to calculate 
mean, and standard error of the mean. The presence and location of signal peptide 
cleavage site in the amino acid sequences of ash pollen allergens was calculated with 
SignalP 4.1,E7 and the theoretical molecular mass of the mature proteins without the 
signal peptide with the ProtParam tool.E8 Alignment of sequences was made using the 
freely available GeneDoc software. 3D structure modeling of the allergens was made 
using SWISS-MODEL, the fully automated protein structure homology-modeling server 
of the Swiss Institute of Bioinformatics (http://swissmodel.expasy.org/).E9 Models 
obtained were represented with VMD.E10 
  
Supplementary References 
E1. Barderas R, Purohit A, Rodriguez R, Pauli G, Villalba M. Isolation of the main allergen 
Fra e 1 from ash (Fraxinus excelsior) pollen: comparison of the natural and 
recombinant forms. Ann Allergy Asthma Immunol 2006; 96:557-63. 
E2. Barderas R, Purohit A, Papanikolaou I, Rodriguez R, Pauli G, Villalba M. Cloning, 
expression, and clinical significance of the major allergen from ash pollen, Fra e 1. J 
Allergy Clin Immunol 2005; 115:351-7. 
E3. Rodriguez R, Villalba M, Monsalve RI, Batanero E. The spectrum of olive pollen 
allergens. Int Arch Allergy Immunol 2001; 125:185-95. 
E4. Barderas R, Villalba M, Rodriguez R. Che a 1: recombinant expression, purification and 
correspondence to the natural form. Int Arch Allergy Immunol 2004; 135:284-92. 
E5. Mas S, Barderas R, Colas C, Quiralte J, Rodriguez R, Villalba M. The natural profilin 
from Russian thistle (Salsola kali) contains a low IgE-binding ability isoform--
molecular and immunological characterization. FEBS J 2012; 279:4338-49. 
E6. Rodriguez R, Villalba M, Batanero E, Palomares O, Quiralte J, Salamanca G, et al. 
Olive pollen recombinant allergens: value in diagnosis and immunotherapy. J Investig 
Allergol Clin Immunol 2007; 17 Suppl 1:4-10. 
E7. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating signal 
peptides from transmembrane regions. Nat Methods 2011; 8:785-6. 
E8. Wilkins MR, Gasteiger E, Bairoch A, Sanchez JC, Williams KL, Appel RD, et al. 
Protein identification and analysis tools in the ExPASy server. Methods Mol Biol 1999; 
112:531-52. 
E9. Arnold K, Bordoli L, Kopp J, Schwede T. The SWISS-MODEL workspace: a web-
based environment for protein structure homology modelling. Bioinformatics 2006; 
22:195-201. 
E10. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph 
1996; 14:33-8, 27-8. 
 
 




Table E1. Clinical data of the ash pollen sensitized patients included in the study 1 
RAST Skin test (D+d)/2 (mm) ELISA (OD at 492 nm) 
Patient 







1 F  3 7.45 4.5 9 0.62 0.92 
2 F  2 2.77 5 7 0.17 0.17 
3 M  3 7.03 5.5 - 0.11 0.11 
4 F  2 2.27 7.5 5 0.23 0.43 
5 F  4 17.8 6.5 8.5 0.31 0.37 
6 M  3 13 8 8.5 0.14 0.15 
7 M  3 11.7 6.5 8.5 0.55 0.69 
8 M  3 4.95 5.5 8.5 0.81 1.28 
9 M  6 >100  4 5 0.74 1.12 
10 F  2 1.42 6.5 7.5 0.24 0.32 
11 F  2 3.35 4.5 9 0.33 0.32 
12 M  2 1.14 4.5 6.5 0.15 0.12 
13 F  3 16.5 4.5 4.5 0.50 0.89 
14 F  3 4.95 6 10 0.19 0.24 
15 F  2 1.19 6.5 9.5 0.09 0.10 
16 M  3 5.26 5.5 8 0.32 0.63 
17 F  4 25.4 6.5 10 0.92 1.12 
18 F  5 56.9 3.5 7.5 0.43 0.53 
19 M  3 7.36 6.5 14 0.24 0.35 
20 M  2 2.34 7 - 0.20 0.18 
21 F  4 21.7 5 9 0.35 0.62 
22 M  2 2.64 6 - 0.41 0.64 
23 M  2 0.83 4.5 6.5 0.23 0.18 
24 F  3 16.1 6 4.5 0.07 0.06 
25 M  4 49.4 6.5 8.5 0.52 0.95 
 2 
Patients were recruited according to a positive cutaneous test response to ash pollen extract and absence 3 
of a migratory background to or from Mediterranean area. Patients age ranges between 18 to 63 years 4 
(mean 28.5 years).  5 
*F, female; M, male. 6 
-, Not done.  7 
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Table E2: Oligonucleotides used to clone ash pollen allergens by PCR. 8 
Allergen Forward primer 5'->3' Reverse Primer  5'->3' 
Fra e 2 ATG TCN TGG CAR RCN TAY GT TTA RAA NAT YTT NGC NAC RTC YTT 
Fra e 3 ATG GCC GAC GAT CCA CAG GAA GT CTA GAA GAT TTT TGC AAC ATC CTT GAC 
Fra e 6 ATG GAC GAG GCC CAG TTT TTA RTT NGG YTT RAA RTT NGC 
Fra e 10 ATG CGA GGA ACC GCA TCA AGA GAG GAA TGA GCA 
Fra e 11 ATG GAT GAT AGA GTA CCT ATT CC TTA AGC TTT GGC GGG GGG 
Fra e 12 ATG GCT GAG AAA ACC AAG ATT TTG TTA AAC AAA TTG ATT AAG GGA CTC CTC 
 9 
 10 
